Jonathan J. Cherry

Jonathan J. Cherry has a diverse and extensive work experience in the field of pharmaceuticals and biotechnology. Jonathan J. currently holds the position of Global Project Lead for the Vatiquinone Portfolio at PTC Therapeutics since 2022. Prior to that, they worked at Biogen from 2018 to 2022, where they held various roles including Director of Global Product Development & Commercialization, R&D Project Leader, Director of R&D Business Strategist, and Director of R&D Strategy and Portfolio Leadership.

Before Biogen, Jonathan served as the Head of Preclinical Biology (Consultant) at Orphan Star Therapeutics for a brief period in 2018. From 2015 to 2017, they held the position of Associate Director at RaNA Therapeutics, where they were responsible for screening and core technologies and led preclinical therapeutic programs for Spinal Muscular Atrophy and Friedreich's Ataxia.

Prior to that, they worked at Pfizer's Rare Disease Research Unit from 2013 to 2015 as a Senior Principal Scientist, leading the Spinal Muscular Atrophy programs and the Novel SMN2 Inducers program.

Jonathan's work experience also includes their role as an Assistant Professor at Indiana University School of Medicine from 2010 to 2013, where they studied Spinal Muscular Atrophy and Human Papillomavirus positive cells. Jonathan J. started their career as a Post Doctoral Researcher at UMass Medical School, focusing on the molecular basis of Spinal Muscular Atrophy and the role of human papillomavirus E6 protein in cervical cancer.

Overall, Jonathan J. Cherry's work experience showcases their expertise in preclinical and clinical research, drug discovery and development, and strategic planning in the field of pharmaceuticals and biotechnology.

Jonathan J. Cherry holds a Doctorate degree in Microbiology and Molecular Genetics from the University of Vermont. Jonathan J. also earned a Bachelor of Science degree in Molecular, Cellular, and Developmental Biology from the University of New Hampshire.